COVID-19中的血栓炎症:α2-巨球蛋白能否帮助控制火势?
本文为综述性文章,探讨COVID-19相关凝血病中中性粒细胞、血小板和内皮细胞的作用,并提出儿童因α2-巨球蛋白水平较高而相对受保护。文章建议基础与临床研究应关注α2-巨球蛋白在COVID-19中的潜在作用。
要点
- COVID-19相关凝血病复杂且影响预后。
- 中性粒细胞通过释放胞外网状结构激活凝血和血小板。
- α2-巨球蛋白在儿童期贡献抗凝血酶活性并广谱抑制蛋白酶。
核心结论
- COVID-19相关凝血病复杂且似影响预后。
- 儿童可能因较高α2-巨球蛋白水平而相对免于重症COVID-19。
- 建议将α2-巨球蛋白在COVID-19中的潜在作用纳入基础与临床研究范围。
主要发现
- 中性粒细胞释放胞外网状结构,该结构由组蛋白和蛋白酶包被的DNA构成。
- 中性粒细胞胞外网状结构可激活凝血和血小板,并释放自由基和弹性蛋白酶等蛋白酶。
- α2-巨球蛋白在儿童期尤其贡献血浆抗凝血酶活性,结合广谱蛋白酶,并与细胞因子等炎症介质相互作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The complex COVID-19-associated coagulopathy appears to impair prognosis. Recently, we presented the hypothesis that children are to some extent protected by higher α2 -macroglobulin (α2 -M) levels from severe COVID-19. In addition to endothelial cells, thrombin, and platelets, neutrophil granulocytes also appear to play an important role. Neutrophils extrude extracellular nets, which are histone- and protease-coated web-like DNA structures; activate coagulation and platelets; and release radicals and proteases such as elastase. The unique phylogenetically ancient and "versatile" inhibitor α2 -M contributes particularly during childhood to the antithrombin activity of plasma, binds a broad spectrum of proteases, and interacts with other mediators of inflammation such as cytokines. It is suggested that the scope of basic research and clinical studies would include the potential role of α2 -M in COVID-19.
引用
- Seitz R, Gürtler L, Schramm W, et al. Thromboinflammation in COVID-19: Can α2 -macroglobulin help to control the fire? J Thromb Haemost. 2020. PMID: 33230947. doi:10.1111/jth.15190
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。